GeneDx Holdings Corp. — Director's Dealing 2021

Jul 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sema4 Holdings Corp. (SMFR)
CIK: 0001818331
Period of Report: 2021-07-22

Reporting Person: Leproust Emily M. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-22	Class A Common Stock	C	25000	$0.00	Acquired	25000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Class B Common Stock	$	C	25000	Disposed		Class A Common Stock (25000)	Direct
2021-07-22	Private Placement Warrants	$11.50	A	166666	Acquired		Class A Common Stock (166666)	Direct

Footnotes

F1: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.